LOGO

You are here: 

 



 

  • Algeta agreements triggers milestone payment from Bayer Schering Pharma

    Algeta ASA has concluded two agreements for the manufacture and supply of Alpharadin for future commercial sale. The signing of these agreements triggers a EUR 5 million milestone payment from Bayer Schering Pharma, Algeta's development and commercial partner for Alpharadin.

     

    >> Read more26.07.10

  • Endringer i skattebetingelsene kan stimulere FoU i næringslivet

     Statsministeren bebudet i sin nyttårstale 2010 en dialog om fremtidens verdiskapning. Mer forskning og utvikling (FoU) vil være avgjørende for å sikre vekst. For å få det til, foreslår Norsk Biotekforum endringer i de skattemessige rammebetingelsene for næringslivets FoU-innsats. Forslagene er utformet med sikte på bredden i norsk næringsliv, og ikke spesielt for de bioteknologiske bedriftene.

    >> Read more10.06.10

  • FDA approves Cysview for detection of bladder cancer

    The US Food and Drug Administration (FDA) has approved Cysview(TM), a fluorescence-based procedure for detection of papillary bladder cancer. Photocure will now receive a 10 million milestone payment from GE Healthcare, its US licensee, and will be eligible for undisclosed royalties once the product has been launched.

    >> Read more31.05.10

  • Patent granted to Biotec Pharmacon in USA

    Biotec Pharmacon reports that one of the company's patent applications referring to a combination therapy for cancer treatment has been granted in USA.

    The patent is a composition patent protecting combinations of Biotec Pharmacon's proprietary compound soluble yeast beta-glucan (SBG) as an adjuvant together with monoclonal antibodies for treatment of cancer.

    >> Read more28.05.10

  • Photocure announces results from phase II study with Visonac

    Photocure ASA announces results from its phase II study in acne with Visonac(TM) in combination with its new full face acne lamp. The efficacy results received in the last phase II study in acne with a simplified VisonacTM procedure were not as good as phase II results previously obtained with VisonacTM.

    >> Read more28.05.10

  • Photocure wins patent case against the US Patent and Trademark Office

    The US Federal Circuit Court of Appeals (CAFC) has upheld a lower court's decision stating that the United States Patent and Trademark Office's interpretation of the law when refusing Photocure's request for patent term extension was not reasonable.

    >> Read more12.05.10

  • Algeta selects new Board of Directors

    Dr. Judith Hemberger and Dr. Kapil Dhingra were elected to Algeta's Board of Directors as Non-executive Directors at the Company's annual general meeting held in Oslo on 22 April 2010.

    >> Read more28.04.10

  • Affitech signs strategic alliance with Russian partner

    Affitech A/S, the antibody medicines company, has entered into a research and development collaboration with LLC NTS Plus (Russia). Simultaneously, Trans Nova Investments Limited, with the key beneficiary being Mr Viktor Kharitonin, Chairman of Pharmstandard, has made an equity investment of €20.9m in Affitech.

    >> Read more22.04.10

  • European expert panel recommends Hexvix

    Despite considerable positive evidence, the use of Hexvix has historically differed widely from country to country and between clinics. European recommendations from a consensus group have now been published, which may make the use of Hexvix-guided fluorescence cystoscopy more unison in Europe.

    >> Read more22.04.10

  • Algeta kåret til årets nyskaper

     Næringslivets Hovedorganisasjon i Oslo og Akershus har kåret legemiddelselskapet Algeta til vinner av NHOs nyskapingspris i 2010.

    >> Read more19.04.10

Showing from 1 to 10 of total 75 articles

Norwegian Bioindustry Association

Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98